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to 500/l and platelets 20,000/l w/o transfusion were 13 and
14 days, respectively. TRM included 1 pt each with intracranial
hemorrhage at d 8, multi-organ failure/sepsis at d 28, IPS/ARDS at
d 119, and grade IV GVHD with disseminated adenovirus. 2 of the
4 deaths were in MRD transplants; no serious cases of VOD were
observed. Grade 2–4 GVHD was seen in 5/16 evaluable MUD pts
and 3 of 29 (all sex mismatched) evaluable MRD pts. CMV reac-
tivation was seen in nearly all CMV sero pts; bk activation was
seen in 25 pts and hemorrhagic cystitis in 10. One case of PTLD,
3 graft failures, and adenovirus infection with nephritis, cystitis,
and transient cardiomyopathy in one patient, and fatal hepatitis in
a second patient were also seen. Relapse/# evaluable for different
diseases are: AML 12/26 (46%), imatinib-resistant CML 3/3 MDS
0/5, MM 3/3, NHL 0/3, ALL 0/3, CLL 0/2. Relapse rates in
evaluable MRD pts, 15/29 (52%), were statistically higher com-
pared to MUD pts, 3/16 (19%) (p  .055); marrow (2/8) vs BSC,
(16/37), were comparable. Alemtuzamab has been effective at con-
trolling GVHD but infectious complications are common and high
relapse rates preclude routine use of this approach in MRD pa-
tients with advanced myeloid diseases. Current use of this agent is
depending on donor (MRD vs MUD) and disease (myeloid vs
other) status.
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MISSING KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) LIGAND
CONFERS PROTECTION FROM RELAPSE IN RECIPIENTS OF UNRELATED
HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR AML
Hsu, K.C.1; Malkki, M.2; Gooley, T.A.2; Dupont, B.3; Petersdorf,
E.W.2, International Histocompatibility Working Group HCT-KIR
Component. 1. Memorial Sloan-Kettering Cancer Center, New York,
NY; 2. Fred Hutchinson Cancer Research Center, Seattle, WA; 3.
Sloan-Kettering Institute for Cancer Research, New York, NY.
The relationship between donor inhibitory KIR and recipient
HLA has been proposed as the basis for KIR-driven alloreactivity
by donor natural killer (NK) cells, leading to higher overall survival
(OS) and a reduction in relapse, graft-versus-host disease (GVHD)
and graft rejection in high-risk acute myelogenous leukemia
(AML) patients undergoing HLA-mismatched transplants. Previ-
ous analyses of KIR effects on HLA-mismatched HCT have ap-
plied a “KIR ligand incompatibility model,” which predicts NK
alloreactivity when donors with class I ligands for inhibitory KIR
are paired with recipients lacking the particular class I ligand
group. We have developed an algorithm that recognizes that pop-
ulation frequencies for inhibitory KIR2DL2/3, -2DL1, and -3DL1
are close to 100%, whereas the corresponding class I ligands (HLA
C1-group, C2-group, or Bw4) have population frequencies that
deviate greatly from 100%, leading to the frequent situation of
“missing KIR ligand,” even in HLA-matched transplants. The
“missing KIR ligand model” was applied in an analysis of 1765
unrelated donor HLA-A, -B, -C, -DRB1, and -DQB1 matched and
mismatched HCT pairs from the IHWG. All patients received
myeloablative conditioning followed by infusion of a T-replete
allograft. Using the “missing KIR ligand model,” KIR ligand ab-
sence/presence was correlated with overall survival (OS) and re-
lapse (Table). There was no beneﬁt in OS or relapse for ALL or
CML patients lacking KIR ligand. In contrast, AML patients
lacking KIR ligand demonstrated a signiﬁcantly lower relapse rate
(p0.001), that could be exclusively attributed to the lack of the
HLA C2-group ligand for donor KIR2DL1 (p
0.0001). The
lower relapse likely contributes to the higher OS (p0.04) seen in
these patients. Comparison of the “missing KIR ligand” and “KIR
ligand incompatibility” algorithms was then performed for AML/
MDS (n176), ALL (n137), and CML (n320) patients and
unrelated donors mismatched at HLA-B and/or HLA-C. Neither
model showed a beneﬁt in OS or relapse for any disease group with
exception of the missing ligand model in AML for relapse
(p0.008) This study indicates that lack of HLA C2-group ligand
in the patient with AML is associated with a lower risk of relapse
and improved overall survival, implying that release from
KIR2DL1 inhibition enhances donor NK alloreactivity against
AML. Adoptive immunotherapy with donor NK infusion may be
particularly beneﬁcial in these patients.
Missing KIR Ligand Algorithm and Disease-Speciﬁc Outcome
Overall Mortality Relapse
Hazard Ratio p-Value Hazard Ratio p-Value
AML/MDS
All ligands present (n  105) 1 — 1 —
Any KIR ligand absent (n 
373) 0.86 0.27 0.55 0.001
HLA C2-Group ligand absent
(n  149) 0.73 0.04 0.34 <0.0001
CML
All ligands present (n  230) 1 — 1 —
Any KIR ligand absent (n 
683) 1.1 0.39 1.08 0.68
ALL
All ligands present (n  77) 1 — 1 —
Any KIR ligand absent (n 
297) 1.12 0.49 1.17 0.56
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TRANSFUSIONAL IRON BURDEN AFTER BONE MARROW TRANSPLAN-
TATION
Jastaniah, W.A.1; Harmatz, P.2; Pakbaz, Z.2; Singer, T.2; Fischer, R.2;
Vichinsky, E.2; Walters, M.C.2 1. British Columbia’s Children’s Hos-
pital, Vancouver, BC, Canada; 2. Children’s Hospital Oakland, Oak-
land, CA.
Background: The signiﬁcance of transfusional iron overload
post-BMT for sickle cell disease (SCD) and hematological malig-
nancies has not been well deﬁned. Hence, we performed tests to
assess iron burden before and after BMT that included: serum iron,
ferritin, TIBC, and liver iron concentration (LIC) by liver biopsy
and/or SQUID biosusceptometer (Ferritometer, Model 5700,
Tristan Technologies, San Diego) under the standardized Ham-
burg-Torino-Oakland protocol. We compared results in children
with SCD and AML to those with thalassemia major (TM). Re-
sults: Fifteen children [SCD (N4), TM (N6), and AML
(N5)] received conventional myeloablative allografting at Chil-
dren’s Hospital Oakland (2000–2003). The mean (	SD) age (y) at
BMT was 10	 2.3, 6.8	 5.1, and 5.4	 2.9 among SCD, TM, and
AML patients, respectively. The mean duration of transfusion
exposures was 2.5, 5, and 2 years, respectively. Results of pre-BMT
iron burden are summarized in the Table. Pre-BMT liver histol-
ogy was assessed in 6 patients (SCD 1 and TM 5). Inﬂammation
was present in 4 TM patients and portal ﬁbrosis in 1 SCD and 3
TM patients. Hepatic venoocclusive disease (VOD) developed in
5/15 patients. TM patients were more likely to develop VOD (80
vs 20%) and pre-BMT, nonspeciﬁc inﬂammatory liver changes
were observed in 60% of TM patients (versus 10% of others).
Post-BMT, six patients were treated by regular phlebotomy. There
was poor correlation between serum ferritin and LIC. The serum
ferritin and WBC normalized by 40 months among phlebotomized
patients. However, normalization of LIC required a longer period
of time. The amount of iron removed by phlebotomy correlated
with the change in LIC as measured by SQUID. Conclusion:
Pre-BMT, we observed a signiﬁcant iron burden in children with
SCD, TM, and AML, which, if untreated, persisted post-BMT.
Liver inﬂammation and VOD was increased in TM patients, which
might reﬂect liver injury that is inﬂuenced by the duration of
exposure rather than simply by the magnitude of iron overload.
Phlebotomy is effective in unloading iron post-BMT in SCD and
TM patients. This pilot study showed that serum ferritin is an
unreliable indicator of iron overload post-BMT. The signiﬁcance
of transfusional iron overload in patients with hematological ma-
lignancies remains uncertain, but this study suggests that there is
potential for hepatic injury post-BMT. Ongoing studies are being
conducted to better deﬁne the natural history of iron overload in
post-BMT patients.
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Iron Burden Before BMT (Mean 	 SEM)
Disease N
Serum
Iron
(g/dl)
Ferritin
(ng/ml)
TIBC
(g/dl)
ALT
(U/L)
RBC
(ml/kg)
LIC (mg
Fe/gm liver
dry wt)
TM 6 165  301 1964.3  180 214  16.8 141.7  67.1 561.7  277.4 15.1  1.4
SCD 4 146.5  46.3 2124.5  1053 233  36.3 67.3  39.4 200.8  106.9 14.7  7.3
AML 5 96  0 2229.5  785.5 241  59 31  1.6 311.1  114.8 ND
TM, Thalassemia major; SCD, Sickle cell disease; AML, acute
myelogenous leukemia; TIBC, total iron binding capacity;
ALT, alanine transaminase; RBC, volume RBC transfused;
LIC, Liver iron concentration.
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DESCRIPTIVE ANALYSIS OF CHANGING TOXICITY PROFILES FOR 30
AND 100 DAY MORTALITY AFTER MATCHED RELATED DONOR (MRD)
ALLOGENEIC (ALLO) HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) USING PO VS IV BUSULFAN (BU) BASED CONDITIONING REG-
IMENS
Gupta, S.; Cole, S.W.; Salzman, D.E.; Ashraf, K.; Aggarwal, C.;
Vaughan, W.P. Bone Marrow Transplantation Program, University of
Alabama at Birmingham, Birmingham, AL.
We have been using BU based preparative regimens in ALLO
MRD HSCT for hematological malignancies since 3/92. Prior to
3/99, 135 pts were treated with po BU in BU/Cy2, BU/Cy/VP16,
and BU/Fludara preparative regimens (po group). Between 3/99
and 5/04, 97 pts received iv BU with pharmacokinetic (PK) guided
dosing in one of the same three regimens (iv group). The distri-
bution of diagnoses was similar in the two groups. In the po group
the diagnoses were acute Leukemia (47), NHL (38), CML (37),
HD (10) and other (3). In the iv group the diagnoses were acute
Leukemia (34), NHL (32), CML (20) HD (3) and other (8). The
female/male ratio was also similar in the two groups (po 63/72, iv
44/53). The pts in the iv group were older (45 yrs) (63/97 vs
57/135, p0.0006, 2), had a slightly higher ASBMT relapse risk
score (72% vs 66%, I/HR), a higher ratio of ASBMT HR CML pt
(11/20 vs 12/37) and more pts with less than 10/10 match (8% vs
3%). Despite the higher risk for both relapse and transplant related
mortality in the iv group, the 30 and 100 d mortality was similar for
the two groups (4% and 31% for iv BU: 8% and 28% for po BU).
Deﬁning cause of death as the initiating event or ﬁrst organ failure
that led to death, we found that, not unexpectedly, death due to
Hepatic Veno-Occlusive Disease (HVOD) was eliminated with the
use of PK directed iv BU (0/21 vs 8/34, p0.014, 2). GVHD/
immunodeﬁciency and cardio-pulmonary toxicity were not in-
creased in the higher risk iv group, but these two causes remained
signiﬁcant and together accounted for 67% of the overall non
relapse mortality in the combined population. However, death due
to progression of primary disease was greater in the iv group (9/30
vs 4/38, p0.04, 2) reﬂecting their greater ASBMT relapse risk.
Because of elimination of HVOD and no increase in any other
cause of non-relapse mortality as a result of pharmacokinetic
guided iv BU targeting, we are now able to transplant higher risk
pts without an increase in the 30 or 100 d mortality. These results
are a part of incremental multiple center pharmaceutical and sup-
portive care efforts directed towards increasing the value of my-
eloablative transplants to older and higher risk pt (Table 1).
Cause of Death—100 d Mortality by Route of BU Administration
Progressive
Disease
Veno-
Occlusive
Disease
GVHD/
Immunodeficiency
Cardio-
Pulmonary Others
po 4 8 15 7 4
iv 9 0 7 8 6
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THE REQUIREMENT OF MHC CLASS II FOR DONOR CD4CD25 T
CELL-MEDIATED SUPPORT OF EARLY ALLOGENEIC PROGENITOR CELL
ENGRAFTMENT
Hanash, A.M.; Levy, R.B. University of Miami School of Medicine,
Miami, FL.
CD4CD25 regulatory T cells have recently emerged as a
potential modality for suppression of GVHD and promotion of
allogeneic engraftment. In a fully allogeneic MHC mismatched
model utilizing C57BL/6 (B6) T cell-depleted bone marrow (BM-
TCD) and sublethally conditioned (7.0 Gy TBI) BALB/c recipi-
ents, we have demonstrated that donor CD4CD25 T cells are
capable of supporting multi-potential and lineage-committed do-
nor progenitor activity as well as long-term chimerism and toler-
ance. In order to pursue the potential for clinical application, we
sought to determine molecular and antigenic requirements in-
volved in the initial promotion of allogeneic engraftment. Al-
though an essential role for IL-10 has been demonstrated in certain
regulatory T cell models, augmentation of donor progenitors seven
days post-BMT did not require CD4CD25 T cell IL-10: co-
transplantation of 1  106 B6-wt or B6-IL-10/ CD4CD25 T
cells both signiﬁcantly increased GFP splenic CFU-GM when
transplanted with 2  106 B6-GFP BM-TCD into BALB/c recip-
ients (mean CFU 	 SE: BM alone, 657.5 	 248.2; BM  wt,
1972 	 331.5; BM  IL-10/, 1965 	 401.7; both p
.05 vs. BM
alone). Assessment of the antigenic requirements for activation of
progenitor support demonstrated that donor CD4CD25 T cells
did not require alloreactivity to support progenitors, as BALB/c 
B6 F1 CD4CD25 T cells signiﬁcantly increased B6 CFU-GM
in BALB/c recipients (p
.001 vs. BM alone). However, B6
CD4CD25 T cells failed to augment MHC-disparate C3H/HeJ
CFU-GM in BALB/c recipients (p.05 vs. BM alone), suggesting
that donor CD4CD25 T cells might require recognition of
syngeneic MHC for progenitor support. Indeed, augmentation of
donor CFU-GM was abrogated when B6 CD4CD25 T cells
were co-transplanted with B6-MHC class II/ marrow into
BALB/c recipients (p.05 vs. BM alone). In conclusion, donor
CD4CD25 T cells capable of promoting long-term engraft-
ment and tolerance do not require IL-10 for support of initial
donor progenitor activity, however progenitor support does re-
quire co-transplantation with syngeneic MHC class II-expressing
marrow. Strikingly, there may be distinct antigenic requirements
for promotion of engraftment and suppression of GVHD, suggest-
ing that the CD4CD25 T cells responsible for these effects may
be distinct as well. Further determination of the role of donor
MHC class II may prove essential for proper construction of
CD4CD25 T cell-based allo-engraftment protocols.
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ABSENCE OF CD80/86 EXPRESSION ON DONOR BONE MARROW IS
SUFFICIENT TO CIRCUMVENT T CELL MEDIATED RESISTANCE FOL-
LOWING EXPERIMENTAL “MINI” MHC-MATCHED ALLOGENEIC BMT
Zimmerman, Z.F.; Levy, R.B. University of Miami School of Medicine,
Miami, FL.
Successful MHC-matched allogeneic BMT following non-my-
eloablative conditioning requires overcoming immune mediated
resistance by alloreactive host T cells to achieve engraftment.
Manipulation of donor APC’s may be a clinically feasible strategy
to achieve this aim. In the current study, donor BM from CD80/
86/ mice was transplanted to determine the requirements of
donor APC in eliciting resistance in pre-clinical “mini” (5.5 Gy
TBI) BMT models. Non donor antigen sensitized (“naı¨ve”) and
donor antigen sensitized (“memory”) recipients were transplanted.
“Naı¨ve” C3H.SW (H-2b) mice were transplanted with 4  106
TCD-BMC from B6-wt or CD80/86/ donors. All mice receiv-
ing B6-wt BM displayed brief donor cell presence peaking at day
7–10 post-BMT followed by disappearance (i.e. rejection) 4–5
weeks later. In contrast, C3H.SW mice receiving CD80/86/
marrow achieved and maintained signiﬁcant donor chimerism
(50%) in both B cell and importantly, T cell compartments.
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